New hope for rare leukemia: drug cocktail shows promise
NCT ID NCT06991920
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two newer drugs, blinatumomab and venetoclax, along with standard chemotherapy, for adults with a rare type of leukemia called acute leukemia of ambiguous lineage (ALAL). The goal is to see if this approach improves survival and remission rates. The trial will enroll 50 participants across multiple centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab and venetoclax
- What this could lead to
- If successful, this combination could become a standard first-line treatment for this rare leukemia, improving survival and remission rates.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not be definitive. The drugs can cause serious side effects like infections and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized chemo and transplants aim to beat infant leukemia
- Fine-Tuning MRI scanners to sharpen the picture of the brain
- Could bone marrow from deceased donors cure blood cancers?
- New combo aims to wipe out hidden leukemia cells
- Selective immune cell removal may tame transplant complications
- New drug combo may make cord blood transplants safer for blood cancer patients